Houlihan Lokey Advises Qbtech

Houlihan Lokey is pleased to announce that Qbtech, the market leader in the objective measurement of ADHD symptoms, has received strategic investment from specialist growth equity investor, Verdane to accelerate growth in the ADHD diagnostic software market. The transaction closed on 16 August 2022.

Founded in 2002, Qbtech is a privately owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 13 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the "Best Mental Health Partnership With the NHS".

Verdane is a specialist growth equity investment firm that partners with tech-enabled and sustainable European businesses to help them reach the next stage of international growth. Verdane can invest as a minority or majority investor, either in single companies or through portfolios of companies, and looks to deploy behind three core themes: the digital consumer, software everywhere, and a sustainable society. Verdane funds hold over €4 billion in total commitments and have made more than140 investments in fast-growing businesses since 2003. Verdane’s team of more than 100 investment professionals and operating experts—based in Berlin, Copenhagen, Helsinki, London, Oslo, and Stockholm—is dedicated to being the preferred growth partner to tech-enabled and sustainable businesses in Europe.

Houlihan Lokey served as the exclusive financial advisor to Qbtech’s selling shareholders and assisted in marketing, structuring, and negotiating the transaction on behalf of the company.

This deal further highlights Houlihan Lokey’s deep sector expertise in advising Nordic software businesses, particularly those within the healthcare technology space.